Ester Baiget, CEO of Novonesis, discussed the company's ongoing research into supplements that may enhance the effectiveness of GLP-1 medications like Wegovy and Ozempic during an interview with CNBC. She emphasized that while GLP-1 drugs are effective for weight management, supplements targeting gut health could provide additional long-term health benefits.
This aligns with a broader trend where consumers are increasingly investing in health-related products, as evidenced by a PwC survey indicating that 40% of GLP-1 users are spending more on vitamins and supplements. The global dietary supplements market is projected to grow significantly, from an estimated $209.5 billion in 2025 to $431.7 billion by 2033, driven by rising health awareness.
However, Novonesis faces challenges, with its human health business experiencing an 8% decline in organic sales in the third quarter, primarily due to reduced demand for probiotic supplements in North America. The company, formed from the merger of Novozymes and Chr.
Hansen, holds a substantial market share in enzymes and microbial solutions, which could position it well if its new products prove beneficial for GLP-1 users